Sep 09, 2021 / 08:30PM GMT
Operator
Good afternoon, everyone, and welcome to the Apellis Pharmaceuticals DERBY and Oaks Top Line Phase III Results Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Meredith Kaya, Senior Vice President of Investor Relations and Strategic Finance at Apellis.
Meredith Kaya - Apellis Pharmaceuticals, Inc. - SVP, IR & Strategic Finance
Good afternoon, and thank you for joining us today to discuss the top line results from the DERBY and OAKS pivotal Phase III studies evaluating pegcetacoplan in patients with geographic atrophy or GA. For those participating via conference call, we have made the slides available via webcast. A replay of this call will also be available on our website following the call.
Before we begin, I would like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors
Apellis Pharmaceuticals Inc Announces results from Phase 3 DERBY and OAKS Transcript
Sep 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers